|
Thursday July 26, 1:34 pm Eastern Time Guilford falls on jitters about Parkinson`s drug NEW YORK, July 26 (Reuters) - Shares of biotechnology company Guilford Pharmaceuticals Inc. (NasdaqNM:GLFD - news) dropped on Thursday as investors became nervous about clinical trial results for its experimental drug to treat Parkinson`s disease. Biotechnology giant Amgen Inc. (NasdaqNM:AMGN - news), which has partnered with Guilford to develop the drug, may include data from the Phase II trials in its second-quarter earnings statement, said analyst Matthew Geller of CIBC World Markets. Shares of Baltimore-based Guilford fell $4.39, or about 20 percent, to $17.61 in afternoon trading on Nasdaq. ``The stock is down a lot because some people think that negative results will come out,`` Geller said. But he added there is no evidence the trial would yield poor results. The drug for Parkinson`s, called NIL-A, is one of six important programs in development for Guilford, so Thursday`s stock slump is an overreaction, Geller said. Officials at Guilford and Amgen were not immediately available for comment. Quelle: http://finance.yahoo.com http://www.reuters.com |
|
| aus der Diskussion: | GUILFORD PHARMACEUTICALS - PART III |
| Autor (Datum des Eintrages): | Maiestro (28.07.01 01:01:38) |
| Beitrag: | 50 von 66 (ID:4073563) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |